Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement
November 20, 2024 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement
Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
November 15, 2024 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
August 17, 2024 11:27 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel reports Second Quarter 2024 Financial Results and provides Corporate Updates
Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
August 16, 2024 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel reports Second Quarter 2024 Financial Results and provides Corporate Updates
Sol-Gel Announces the Signing of Six Exclusive License Agreements to Commercialize TWYNEO® and EPSOLAY® in Europe and South Africa
July 25, 2024 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel Announces the Signing of Six Exclusive License Agreements to Commercialize TWYNEO® and EPSOLAY® in Europe and South Africa
Sol-Gel Technologies Announces Management Realignment
July 15, 2024 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel Technologies Announces Management Realignment
Sol-Gel Announces Receipt of Nasdaq Minimum Price Notice
May 28, 2024 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel Announces Receipt of Nasdaq Minimum Price Notice
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates
May 20, 2024 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel
May 16, 2024 06:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel and Beimei Pharma annouce an Asset Purcase Agreement to commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
April 01, 2024 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream